Skip to main content
TipRanks
Go Ultimate75% OFF

Tonix Pharma (TPM0) Q3 2026 Earnings Report

9 Followers

DE:TPM0 Q3 2026 EPS Results

Actual EPS
-EUR 2.63
Consensus EPS
-EUR 2.17
Beat/Miss
Missed by -EUR 0.46
One Year Ago EPS
-EUR 3.27

DE:TPM0 Q3 2026 Revenue Results

Actual Revenue
EUR 15.68M
Expected Revenue
EUR 14.84M
Beat/Miss
Beat by +EUR 834.23K
YoY Revenue Growth
+423.83%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/09/2026
Time
Before Open
Conference Call
Monday, November 9, 2026
DE:TPM0 Upcoming Earnings

Tonix Pharma's next earnings date is estimated for March 15, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:TPM0 Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 09, 2026|% Change Since:-40.33%|
Earnings Call Sentiment|Positive

The call was predominantly positive, led by strong TONMYA sales and prescription growth, improving payer coverage, rising refills, expanded commercial reach, and continued progress across the clinical pipeline. The main challenges were the Dr. Reddy's Paragraph IV patent challenge, materially higher operating expenses, a declining cash balance, uncertainty around some clinical timelines, and the regulatory impasse for TNX-1300.

Company Guidance

Management expects TONMYA’s positive trends to continue into the fourth quarter, with a larger sales force and growing sales, and believes it is “well positioned for a strong fourth quarter and 2027”; the 150-person sales force is targeting roughly 70% of approximately 25,000 HCPs who diagnose and treat fibromyalgia, while coverage reaches approximately 53% of covered lives in the U.S. and is expected to continue expanding. The company expects gross to net fluctuations early in the launch, continued progress in coverage, continued improvement on copay buydowns and approval rates, and “consistent growth” through Q4 through 2027. For TNX-4800, the adaptive Phase II TRAIL study is expected to begin in the first quarter of 2027, enroll approximately 3,300 adults over 2 Lyme seasons, start with a lead-in cohort of approximately 500 participants in the first quarter of 2027, and enroll the balance of the efficacy cohort in the 2028 Lyme season; the company expects safety clearance by the end of the second quarter or early in the third quarter, and expects to begin enrolling in the Phase II study in the first half of 2027. An investigator-initiated Phase II study of TNX-1500 is expected to begin in the first quarter of 2027 at Massachusetts General Hospital, enroll five patients, and has a primary endpoint of 18 months with interim looks at earlier time points. The company expects its cash resources and net proceeds raised from the equity offering after quarter end to meet operating and capital expenditure requirements into early third quarter of 2027, has guided to runway into Q3 of next year, is monitoring expenses and focusing on key programs, and is not yet guiding to HORIZON enrollment completion or top-line timing, although it is hoping to enroll it quickly and provide guidance hopefully sometime soon.

  • TONMYA Sales GrowthThird-quarter TONMYA net sales were approximately $15 million, increasing 37% quarter-over-quarter. Growth was supported by previously signed payer agreements, more favorable gross-to-net adjustments than expected, and execution of the launch strategy.
  • Prescription Growth and Refill MomentumThird-quarter TONMYA prescriptions totaled 16,375, up 28% from the second quarter. New prescriptions grew 17% quarter-over-quarter and refill prescriptions grew 56%. TONMYA outperformed other FDA-approved fibromyalgia-indicated products, which were generally flat during the same period.
  • Expanded Sales Force Driving Broad-Based GrowthThe sales force was expanded to 150 representatives on September 1. Since the expansion, total prescriptions, new prescriptions, refills, new writers, and total writers have all meaningfully increased, with more field activity, broader prescriber reach, and sampling cited as drivers.
  • Expanded Prescriber CoverageThe expanded sales force is targeting roughly 70% of approximately 25,000 health care providers who diagnose and treat fibromyalgia, compared with approximately 40% before the expansion. New writers and total writers have increased at a greater rate since September 1.
  • Improving Market AccessTONMYA coverage reached approximately 53% of covered U.S. lives. Tonix signed multiple commercial and government payer agreements in 2026, including two managed Medicare agreements in the third quarter. Commercial approval rates increased, bridge prescriptions through BlinkRx declined, prior authorization submission and approval rates remained strong, and third-party field access managers were added.
  • Improving Prescription EconomicsAverage price per prescription continued to increase as the mix shifted toward 60-count bottles versus 30-count bottles. The company also reported increasing approvals, declining copay buydown contributions, and a lower percentage of bridge prescriptions as coverage expanded.
  • Positive Prescriber and Patient FeedbackPrescriber feedback remained positive. Management reported anecdotal feedback of good efficacy and a strong tolerability profile, with some physicians saying patients viewed TONMYA as life-changing compared with prior treatments. The company also reported increasing persistence and refills.
  • Growing TONMYA Awareness and Promotional ActivityUnaided awareness of TONMYA has doubled since February, and more than 80% of surveyed health care providers recognize TONMYA when prompted. Tonix sponsored a Good Morning America segment, conducted a media tour that generated 20 interviews across major U.S. markets, participated in 13 congresses, and supported more than 130 peer-to-peer sessions during the quarter.
  • Strong Revenue Increase and Stable Cost of SalesThird-quarter net product revenue was approximately $17.2 million, consisting of approximately $15 million from TONMYA and $2.2 million from Zembrace SymTouch and Tosymra. This compared with $3.3 million in the third quarter of 2025. Cost of sales was approximately $1.3 million versus $1.4 million in the prior-year period, with the decrease attributed to product mix.
  • Progress on HORIZON Depression StudyTonix is enrolling participants in HORIZON, a Phase II potentially pivotal study of TNX-102 SL as a first-line monotherapy for adults with major depressive disorder. The program could support a potential label expansion for TONMYA and targets disturbed sleep of depression through antagonism at four neuronal receptors.
  • TNX-4800 Lyme Program Advances Toward Phase IIThe FDA confirmed overall agreement with the randomized, placebo-controlled adaptive field-study design for TNX-4800. Tonix submitted the protocol to the FDA, is manufacturing investigational product, has selected a CRO partner, and remains on track to deliver product to study sites in the first quarter of 2027. The planned study is expected to enroll approximately 3,300 adults over two Lyme seasons, beginning with an approximately 500-participant lead-in cohort.
  • Significant Lyme Disease Market OpportunityA third-party commercial assessment estimated that approximately 118 million U.S. adults may be at risk of Lyme disease because they live, work, or travel in high-risk endemic areas. Providers and payers cited high awareness and concern about Lyme disease, potential clinical differentiation for TNX-4800, and Lyme prevention as the most significant unmet need.
  • TNX-1500 Kidney Transplant Program Moving to Phase IIAn investigator-initiated Phase II study of TNX-1500, also known as mosdaprubart, is expected to begin at Massachusetts General Hospital in the first quarter of 2027 and enroll five patients. The study will significantly reduce conventional immunosuppressive drug dosing, while Tonix aims to preserve durable half-life and selected Fc-related effector functions with improved safety and tolerability relative to first-generation anti-CD40 ligand antibodies.
  • TONMYA Intellectual Property ProtectionManagement stated that TONMYA's currently granted core patents provide protection into 2034 and cover the eutectic formulation technology and other unique product characteristics.
  • Cash Runway and Potential PartnershipsTonix ended the quarter with approximately $162.8 million in cash and cash equivalents. Management stated that cash resources as of September 30, 2026, together with net proceeds from an equity offering completed after quarter end, are expected to meet operating and capital expenditure requirements into early third quarter of 2027. The company is also in discussions with potential partners.

DE:TPM0 Earnings History

DE:TPM0 earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 15, 20272026 (Q4)-2.33--3.62――
Nov 09, 20262026 (Q3)-2.17-2.63-3.2719.50% (+0.64)
Aug 10, 20262026 (Q2)-2.40-2.22-3.5136.79% (+1.29)
May 11, 20262026 (Q1)-2.34-2.67-2.58-3.17% (-0.08)
Mar 12, 20262025 (Q4)-2.90-3.62-8.8959.26% (+5.27)
Nov 10, 20252025 (Q3)-3.26-3.27-20.9284.39% (+17.66)
Aug 11, 20252025 (Q2)-2.52-3.51-1753.9899.80% (+1750.47)
May 12, 20252025 (Q1)-2.81-2.58-524.0199.51% (+521.43)
Mar 18, 20252024 (Q4)-16.83-8.89-19941.4999.96% (+19932.60)
Nov 12, 20242024 (Q3)-352.98-20.92-5327.4399.61% (+5306.51)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed